Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rIL-21 plus Sunitinib in Stage IV Renal Cell Carcinoma
NCT00617253Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2007
- Primary completion
- Jun 2008
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
A Phase 2 trial of recombinant human interleukin 21 in renal cell carcinoma (RCC), sponsored by Novo Nordisk. Started Jul 2007; status: completed.
02
Drugs
recombinant human interleukin 21
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00617253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00617253.